As of Feb 03, 2025, ResMed Inc.'s Discounted Cash Flow (DCF) valuation estimates its share price at $144.1. This suggests it may be overvalued by (40.1%) compared to its current price of around $240.6, using a WACC of 7.6% and growth rates of 3.0%.
As of Feb 03, 2025, ResMed Inc.'s Weighted Average Cost of Capital (WACC) is approximately 7.6%.
As of Feb 03, 2025, ResMed Inc.'s Enterprise Value (EV) is approximately $21.8B. This value reflects the company's total market capitalization plus debt, minus cash and cash equivalents, providing a comprehensive measure of its overall value in the market.